ADF Awards

The ADF announces various prizes to reward scientists / researchers from the field of dermatological research. In addition to the Paul Langerhans Award for established researchers and the Egon Macher Award for young investigators outstanding works in the field of allergy research (ADF / ECARF Award of European Allergy Research) and oncology (Dermato Oncology Junior Scientist Award) will be honored on the ADF Annual Meetings.

In addition, the best posters will be awarded with a poster prize.

For the complete tender texts and the detailed allocation policies please click on the highlighted link.

Please note:
For poster prices, the ADF / ECARF Award for European Allergy Research, the Dermato Oncology Junior Scientist Awards and for the Translational Research Award, a separate application is not necessary. For these prices all abstracts submitted before the deadline will be evaluated.
Submissions for the Paul Langerhans Award and the Egon Macher Award should be made in all cases exclusively in electronic form as one PDF file to the ADF office.
Submission deadline: November 01.

Back

Translational Research Award

- donated by Novartis Pharma GmbH - NEW: To be continued in 2018!

From 2006 to 2014, the ADF was able to offer two prizes in the field of Translational Research, which were awarded by the Foundation Dermatologikum Hamburg every second year. From 2018 on we are able to offer six prizes per year supported by Novartis Pharma GmbH.

These prizes will be awarded to researchers in the field of Dermatology who are attempting to transfer insights gained in experimental basic research into clinical applications. Junior scientists who present outstanding and innovative work in this field are preferably considered.

Awarded are 6 x 2.500,- EUR.

An independent scientific advisory board consisting of former ADF board members, clinic directors and leader of specific centers within dermatological clinics will select and nominate the awardees.

The Translational Research prizes will be awarded at the ADF Annual Meeting to researchers or clinician scientists (first or senior authors) who performed outstanding work in the field of Translational Research. The Translational Research prizes will cover six different focus areas of dermatological research.

The prizes, which are awarded in six different disciplines of dermatological research, will be awarded to first / senior authors during the ADF anniversary, which will carry out outstanding work in this field. Each application for the Translational Research Prize is reviewed by a number of members of the Board of Trustees, with the appraisers assigned to the individual applications in the batch process (to the exclusion of a possible bias). Subsequently, each reviewer evaluates the assignments assigned to him using a standardized point system according to the innovation and originality of the submitted work, their relevance and their possible potential for translation into clinical application. The work with the highest score in each category is awarded, whereby the division of the prizes is possible for the same number of points.

All contributions to clinical translation research that were submitted as an abstract on time to the ADF Annual Meeting will be considered.

Board of trustees:

  • Prof. Dr. Jens Malte Baron (Vorsitz)
  • Prof. Dr. Markus Böhm
  • prof. Dr. Cristina Has
  • Prof. Dr. Cornelia Mauch
  • Prof. Dr. Martin Metz
  • Prof. Dr. Michael Schön
  • Prof. Dr. Knut Schäkel
  • Prof. Dr. Michael Sticherling

Past awardees of the Translational Research Award


2018
Farzan Solimani, Marburg
Therapeutic inhibition of IL-17 leads to clinical remission of lichen planus

2018
E. Zanuttigh, München
The secretome of skin cancer cells influences the transcriptome of keratinocytes

2018
Lenche Chakievska, Lübeck
Rationale for anti-IL-17A treatment in bullous pemphigoid

2018
Henning Wiegmann, Münster
LEKTI is substrate of Transglutaminase-1: implication for a therapeutic topical replacement strategy for Netherton Syndrome

2018
Maria Schneeweiß, Münster
Topical treatment with a novel kappa-opioid receptor agonist ameliorates atopic dermatitis

2018
Tobias Sinnberg, Tübingen
Inhibition of melanoma cell derived prostaglandin E2 amplifies T- cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy

2014
A. Stegemann, Münster
Beta-endorphin - an emerging antifibrotic neuropeptide

2014
N. Wagner, Heidelberg
RAGE ligands S100A8/A9 and HMGB1 as prognostic markers in melanoma

2012
J. Stehn, Sydney
Developing chemotherapeutics which selectively disable the actin cytoskeleton of tumor cells

2012
Misa Hirose, Lübeck
Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen

2010
Katja Bieber, Lübeck
Modulation of experimental epidermolysis bullosa acquisita towards an improved phenotype by initiating the production of non-pathogenic autoantibodies

2008
J. S. Kern, Freiburg
Cell therapy restores skin function in an immunocompetent mouse model for dystrophic epidermolysis bullosa

2010
Robert Sabat, Berlin
Interleukin(IL)-22, a T-cell mediator, induces in keratinocytes IL-20, a tissue cell mediator: a novel cascade with major relevance for the pathogenesis of psoriasis The epidermal alterations in psoriasis are mediated by IL-22, but not by other T-cell mediators including IL-17 or IFN-, and are amplified by TNF-alpha.

2008
Thomas Volz, Tübingen
Induction of IL-10 producing suppressor T cells by non-pathogenic gram-negative bacteria clears atopic dermatitis

2006
E. Gaffal, Bonn
Contact hypersensitivity is significantly increased in cannabinoid receptorknockout mice: Evidence for the involvement of the endogenous cannabinoidsystem in the regulation of cutaneous immune responses.

2006
S. Meyer, Regensburg
High-throughput tissue microarray analysis of MTAP expression inmelanocytic skin tumors.